Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.
Also called NCT01960179
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 361 participants
- Sponsor
- Registry
-
NCT01960179
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01960179. Allocation not applicable; no masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2015-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- lixisenatide AVE0010
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01960179- Content hash
74d04262b2fcbe24896207d01312a89d9ee36277d6516401e98530acb621b514